The plan calls for 45 thousand jobs at full buildout. Already there is a $10 Billion dollar annual economic impact in a single square mile….
Innovation is happening. Right here.
Fitzsimons Innovation Community is a sprawling campus of leading-edge laboratory workspace where innovative health and life sciences companies of all sizes take their research to the next level to cure diseases, save lives, and improve care. Move in, and build your vision here—today.
The emphasis is on Community
We called it a community for a reason. From the board of directors to the newest company on campus, everyone at Fitzsimons Innovation Community knows that easy access to collaboration has direct results on success. From idea incubation to final-product manufacturing, your end-to-end innovation can come alive right here on our campus. All that Colorado sunshine is just a bonus.
Cutting-edge discoveries in action
Fitzsimons Innovation Community member companies are thriving. 91% of companies reported either no change to workforce or added employees.
Fitzsimons Innovation Community member companies received more than 12 patents for their innovations in 2021, a 50% increase over the prior year.
Fitzsimons Innovation Community member companies introduced more than 16 new innovations to the market in 2021, from pharmaceuticals to molecular biology to medical devices.
In 2021, Fitzsimons Innovation Community member companies attracted more than $25M in investments to advance R&D, accelerate commercialization, support clinical trials, and fine-tune technology.
Companies with Discoveries
Fitzsimons Innovation Community member companies made news with major breakthrough discoveries last year. Areas included pharmaceuticals, cell and gene therapy, medical devices, molecular biology, and diagnostics.
Fitzsimons Innovation Community member companies appreciate access to resources, opportunities to interact, proximity to research institutions, and the value offered by Community membership.
*Fitzsimons Innovation Community Member Growth Survey responses (January – December 2021)
A heritage of healthcare and innovation
Fitzsimons Innovation Community stands on the grounds that once held the Fitzsimons Army Hospital, where soldiers returning from World War I were treated. The Colorado high altitude has always been a destination for advancements in lung treatment, and 100 years ago, soldiers sought cures for tuberculosis and mustard gas exposure right here.
After the Army decommissioned the hospital in the 1990s, ideas for the current University of Colorado Anschutz Medical Campus and Fitzsimons Innovation Community began to percolate. That rich history of discovery, care, and research continues to inspire our vision a century later.
Our team is on your team
You know best when it comes to your projects, and we know how to keep you up and running with first-class scientific facilities management and community engagement. Our priority is to help you thrive on this campus and we have the proven tools and expertise to make that happen.
COMMUNITY SERVICE MANAGER
Vp, business development
Erica N. Slaughenhoup
PRESIDENT & CEO
Senior property manager
Vp, finance & operations
“The workspace has been perfect for our projects, but the most impressive thing to me has been the community. We’ve collaborated with researchers from the CU Anschutz Medical Campus, networked with other Fitzsimons Innovation Community members, and bounced ideas off some of the best minds in healthcare. And it’s all contributed to us moving forward in our research.”
“I park my car in the morning, and then I never move it until I leave after work. We walk to lunch and meetings and take advantage of the outdoor space as much as we can during the day. Work-life balance happens right on campus.”
Fitzsimons Innovation Community News
The award recognizes the investments Fitzsimons Innovation Community is making to advance Colorado’s life sciences community and better position the entire ecosystem for growth
Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials
Congresswoman Diana DeGette (D-CO) visits the Gates Biomanufacturing Facility's Protein Suite, in which GMP-grade AV-1980R was manufactured for the Institute for Molecular Medicine's phase 1 clinical...
Explore how Atara's investigational EBV T-cell platform-based therapies target cancer and autoimmune diseases are manufactured.
Rather than just redirecting flow, implantations provide therapy to heart cells and drive new tissue
Ceria Therapeutics, Inc. Awarded a $300,000 SBIR Grant to Advance Development of a Novel Treatment of Non-Healing Diabetic Foot Ulcers
Ceria Therapeutics, Inc. (Ceria), a Colorado-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a second Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to development of CTX-001 for the treatment of non-healing diabetic foot ulcers (DFUs).
University of Colorado faculty this year attracted $1.46 billion in sponsored research funding and gifts supporting research. The support powers wide-ranging discovery and impact, ultimately benefiting Colorado, the nation and the world.
Foresight Diagnostics, Inc, a leader in cancer diagnostics and cancer relapse testing, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company patent No. 11,447,833 for the detection of minimal residual disease (MRD) using its personalized phased variant detection platform. "We are pleased that the USPTO has recognized the novel nature of our proprietary technology and are excited about the impact we believe this technology will have on the lives of cancer patients," said Dr. Jake Chabon, Ph.D., Chief Executive Officer of Foresight Diagnostics.
Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen
"Ventria’s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation"
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics and their partner Pierre Fabre Group announce that the European Medicines Agency's CHMP issued a positive opinion for their investigational therapy to treat adult and pediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.
The plan calls for 45 thousand jobs at full buildout. Already there is a $10 Billion dollar annual economic impact in a single square mile....
Phone. Address. Email.
Want to stay on top of what’s happening on campus?
Sign up for regular updates from Fitzsimons Innovation Community.
Thank you for subscribing!